| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| HUNT DOUGLAS M | The Reporting Person is the Senior Vice President of Regulatory Affairs of the Issuer. | C/O PUMA BIOTECHNOLOGY, INC., 10880 WILSHIRE BLVD., SUITE 2150, LOS ANGELES | /s/ Gordon Esplin as attorney-in-fact for Douglas M. Hunt | 08 Jan 2026 | 0001727172 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | PBYI | Common Stock | Sale | $23,218 | -3,973 | -2.4% | $5.84 | 160,921 | 06 Jan 2026 | Direct | F1 |
| transaction | PBYI | Common Stock | Sale | $29,477 | -5,014 | -3.1% | $5.88 | 155,907 | 07 Jan 2026 | Direct | F1 |
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
| Id | Content |
|---|---|
| F1 | Adoption date of referenced 10b5-1(c) plan is: 12-14-2020 |
The Reporting Person is the Senior Vice President of Regulatory Affairs of the Issuer.